TLRY Stock Chart & Stats
C$6.24
C$0.23(4.19%)
At close: 4:00 PM EDT
C$6.24
C$0.23(4.19%)
Day’s Range― - ―
52-Week RangeC$5.19 - C$32.30
Previous CloseN/A
Volume429.78K
Average Volume (3M)524.40K
Market Cap
C$863.74M
Enterprise ValueC$780.77
Total Cash (Recent Filing)C$231.27M
Total Debt (Recent Filing)C$398.40M
Price to Earnings (P/E)―
Beta1.88
Next Earnings
Oct 08, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.33
Shares Outstanding147,782,140
10 Day Avg. Volume533,800
30 Day Avg. Volume524,403
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.38
Price to Sales (P/S)0.67
P/FCF Ratio-6.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$7.55Price Target Upside20.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.7
Revenue Forecast (FY)C$1.58B
Bulls Say, Bears Say
Bulls Say
International Cannabis GrowthStrong international cannabis growth, led by Germany, the U.K., Poland, and Italy, demonstrates expanding demand and geographic reach. Rising medical flower volumes and Portuguese production capacity provide a foundation for further scale, utilization, and potential operating leverage.
Liquidity And Debt ReductionA sizeable liquidity position and near-zero net debt give Tilray greater flexibility to fund operations, manage maturities, and pursue growth initiatives. Debt reduction also lowers financial pressure, although the company still needs to convert liquidity strength into self-funded cash generation.
Distribution Platform StrengthThe distribution business provides meaningful scale and broad access to pharmacies and wholesalers, supporting recurring product flow across established channels. Revenue growth and improved gross margin indicate that this platform can contribute durable diversification beyond cannabis cultivation and retail exposure.
Bears Say
Persistent Losses And Cash BurnOngoing net losses and negative adjusted free cash flow show that Tilray has not yet reached sustainable profitability or internally funded growth. Continued cash consumption can constrain investment choices and leave execution dependent on liquidity management, financing, or further operating improvements.
International Cannabis Price CompressionPrice compression directly reduces the profit captured from international cannabis growth, limiting the benefit of higher volumes and market expansion. If pricing pressure persists, Tilray may need continued cost reductions and mix improvements merely to protect margins as the segment scales.
BrewDog Working-capital StrainThe BrewDog acquisition has required substantial working-capital investment and has delayed cash conversion, increasing the gap between reported revenue and usable cash. This can weigh on near-term liquidity efficiency and makes integration, receivables recovery, and operating discipline important to value creation.
Tilray News
TLRY FAQ
What was Tilray’s price range in the past 12 months?
Tilray lowest stock price was C$5.19 and its highest was C$32.30 in the past 12 months.
What is Tilray’s market cap?
Tilray’s market cap is C$863.74M.
When is Tilray’s upcoming earnings report date?
Tilray’s upcoming earnings report date is Oct 08, 2026 which is in 9 days.
How were Tilray’s earnings last quarter?
Tilray released its earnings results on Jul 28, 2026. The company reported -C$0.609 earnings per share for the quarter, missing the consensus estimate of -C$0.017 by -C$0.592.
Is Tilray overvalued?
According to Wall Street analysts Tilray’s price is currently Undervalued.
Does Tilray pay dividends?
Tilray does not currently pay dividends.
What is Tilray’s EPS estimate?
Tilray’s EPS estimate is -0.23.
How many shares outstanding does Tilray have?
Tilray has 147,782,140 shares outstanding.
What happened to Tilray’s price movement after its last earnings report?
Tilray reported an EPS of -C$0.609 in its last earnings report, missing expectations of -C$0.017. Following the earnings report the stock price went down -2.465%.
Which hedge fund is a major shareholder of Tilray?
Currently, no hedge funds are holding shares in TSE:TLRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tilray Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$7.55 (20.96% Upside)
C$7.55 (20.96% Upside)
Blogger Sentiment
Bullish
TSE:TLRY Sentiment 62%
Sector Average 64%
Sector Average 64%
Insider Transactions
Bought Shares
Worth C$96.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.29%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
11.31%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Tilray
Tilray Brands, Inc. is a diversified global consumer packaged goods company primarily involved in the cultivation, processing, marketing, and sale of cannabis products. Its operations span a significant international footprint, encompassing Canada, the United States, Europe, Australia, New Zealand, and Latin America. The company organizes its business across four distinct divisions: Cannabis, Distribution, Beverage Alcohol, and Wellness. Within its cannabis division, Tilray provides a comprehensive range of medical and adult-use items, including regulated products like GMP-certified cannabis flowers, oils, vaporizers, edibles, and topical applications. Beyond cannabis, Tilray's portfolio extends to the procurement and resale of pharmaceutical and wellness goods. Furthermore, it manufactures, promotes, and distributes a variety of alcoholic beverages, alongside hemp-derived food and other wellness items. The company markets its diverse offerings under numerous recognized brands, such as Tilray, Aphria, SweetWater, and Breckenridge Distillery. Its products reach a wide array of customers, including retail outlets, wholesale partners, medical patients, healthcare practitioners, hospitals, pharmacies, scientific researchers, governmental bodies, and directly to end consumers. Formerly operating as Tilray, Inc., the corporation is headquartered in Leamington, Canada.
TLRY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted meaningful operational progress: record revenue and adjusted EBITDA, stronger liquidity (≈$235M cash) and near-zero net debt, substantial international cannabis and distribution growth, and strategic beverage expansion through the BrewDog acquisition and the Carlsberg partnership. At the same time, challenges remain including a FY2026 net loss of $105.2M, negative adjusted free cash flow (negative $86M), international price compression (~$21M), legacy U.S. beverage headwinds, and significant working capital tied up in the BrewDog transaction. Overall the company presented a pathway to higher margins and cash generation but still faces execution and market-mix headwinds in the near term.View all TSE:TLRY earnings summariesTLRY Stock 12 Month Forecast
Average Price Target
C$7.55
▲(20.96% Upside)